Psoriatic Arthritis

Patients with psoriasis on biological agents might have a lower PsA risk than those on methotrexate, but patients on topical therapy have an even lower risk, a study found.

Among patients with PsA, men tend to present more peripheral joint movement, and women tend to exhibit more axial involvement, a new study found.

Adults with active PsA treated with guselkumab exhibited durable achievement of study endpoints associated with disease control, irrespective of baseline characteristics.

The approval was based on previous data from well-controlled RA studies coupled with findings from a multinational, dose-finding study of pediatric patients with pJIA.

cfPWV values were significantly higher in patients with PsA compared with controls, even after adjusting for confounders.

The approvals were based on data from well-controlled studies of the drug in adult patients with PsA and RA.

Benjamin J. Smith, DMSc, PA-C, discusses the importance of defining comorbidities in diagnosing PsA, as well as prescribing biologics.

After initiating treatment with ixekizumab, tender and swollen joint counts, pain, fatigue, and body surface area affected by psoriasis were significantly improved.

Nigil Haroon, MD, PhD, explains how understanding the "window of opportunity" is crucial in treating axial spondyloarthritis.

Combining algorithms SCORE2 and QRISK3 created the best predictive model to predict the cardiovascular risk for patients with PsA.

These data highlight the role of the National Health Service, though the relationship between socio-economic background and health outcomes remains complex.

An analysis of more than 1800 adults with psoriatic arthritis found more than 20% of patients report widespread pain, with 10% meeting fibromyalgia criteria.

An IMID diagnosis or use of immunomodulatory medications were not shown to be a significant risk factor of severe COVID-19 outcomes.

Those with coexisting PsA and atopic dermatitis needed to switch to a higher number of biologics to achieve disease control.

Both overall TEAEs and serious TEAEs were numerically higher in those receiving upadacitinib compared with adalimumab.

Patients often rely on opioids a year before and a year after a diagnosis of ankylosing spondylitis, psoriatic arthritis, or rheumatoid arthritis.

Using a cut-off value of 7.1 kPA for liver stiffness, results of the transient elastography yielded 100% sensitivity and 68% specificity among this patient population.

Treatment with risankizumab was shown to be an effective strategy among patients with PsA regardless of varying demographic and psoriatic disease characteristics through 1 year.

Post-treatment with risankizumab, the cDAPSA score, PGA score, and PASI score substantially decreased among a cohort of patients with psoriatic arthritis.

A pooled analysis revealed a loading-dose regimen, especially for patients receiving secukinumab 150 mg for PsA, increases the odds of disease improvement.

This post-hoc analysis of phase 3 data, using GRAPPA-recognized PsA domains, highlighted disease improvements following treatment with guselkumab.

Despite these conclusions, this meta-analysis also showed that those receiving PDE4 inhibitors were the least likely to report adverse events.

Philip J Mease, MD, highlights recent data comparing the safety and efficacy of bimekizumab with other DMARDs for the treatment of PsA.

Patients with higher disease activity reported the highest perceived consequence of disease.

This month’s rheumatology month in review showcases the efficacy of various medications for the treatment of psoriatic arthritis, underscores the importance of addressing workforce challenges, and explores non-pharmacological interventions.

Dermatologist and rheumatologist Saakshi Khattri highlights the importance of screening psoriasis patients for psoriatic arthritis and how that may impact treatment decisions.

At week 52, investigators noted an overall improvement of 93% in PASI scores from baseline.

The selective, allosteric tyrosine kinase 2 inhibitor demonstrated significant and clinically meaningful improvements in PROs versus placebo in a phase 2 trial of patients with PsA.

These data highlight the changes observed in cytokine levels among both PsA treatment responders and non-responders.

Bimekizumab initiation resulted in greater or comparable efficacy regarding minimal disease activity and achievement of ACR50/70 compared with guselkumab.